Curt D. Furberg, a native of Sweden, worked for 11 years at the US National Heart, Lung, and Blood Institute and now teaches at Wake Forest University School of Medicine. Dr. Furberg is a member of the US FDA Advisory Committee on Drug Safety and Risk Management.
Health hazards – nuclear reactors, guns, and contaminated foods – surround all of us, so governments take an active role in limiting these hazards through regulations, which, in many cases, are very successful. But the situation is far different concerning the safety of prescription drugs. Indeed, as far as protecting the public is concerned, drug safety is the regulator’s neglected stepchild.
The magnitude of the problem is huge. In the United States alone, it is estimated that every year up to 100,000 patients die due to serious adverse drug reactions (ADR’s). If true, drug-induced death would qualify as the fourth or fifth leading cause of death (depending on which mortality estimates are used). Moreover, the direct annual hospital costs attributable to ADR’s run into the billions of dollars, and this does not include all the suffering that ADR’s cause that does not lead to hospitalization (or death).
The difficulties in determining cause and effect must be acknowledged. Whether a patient’s death or hospitalization is due to a particular drug, the underlying illness, or a combination of the two can be hard to determine. But this makes drug safety all the more important.
To continue reading, register now.
Subscribe now for unlimited access to everything PS has to offer.
Subscribe
As a registered user, you can enjoy more PS content every month – for free.
Register
Already have an account? Log in